3189 results for «686»

Filter By

3189 results

Team approach to structural heart disease: how to handle unexpected situations

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...

Team approach to structural heart disease: how to handle unexpected situations

From diagnosis to device: decision-making and planning for mitral valve interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

This session offers a structured approach to mitral TEER, integrating advanced imaging techniques for detailed mitral valve morphology evaluation, procedural planning, and complication prediction. It highlights device selection considerations and emerging technologies to tailor interventions for complex mitral valve disease, supported by multiple case presentations and...

From diagnosis to device: decision-making and planning for mitral valve interventions

Healthcare professionals in the structural heart disease treatment

15 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the essential roles and contributions of various healthcare professionals involved in structural heart disease treatment. It offers insights into the unique responsibilities of medical technologists, nurses, and radiological technologists across preoperative, intraoperative, and postoperative stages, fostering collaboration and sharing practical tips to strengthen...

Healthcare professionals in the structural heart disease treatment

Complications and bailout strategies in transcatheter mitral interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.

Complications and bailout strategies in transcatheter mitral interventions

Transcatheter electrosurgery and leaflet modification of the aortic valve

15 Feb 2026 – From PCR Tokyo Valves 2026

This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...

Transcatheter electrosurgery and leaflet modification of the aortic valve

TAVI: new evidence and clinical trials

14 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest evidence from head-to-head clinical trials comparing contemporary TAVI devices, including detailed discussions of the LANDMARK and COMPARE trials. It also highlights ongoing and upcoming clinical trials poised to influence guideline recommendations and expand the therapeutic scope of TAVI, providing crucial insights...

TAVI: new evidence and clinical trials

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

18 May 2021

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Authors :

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial

26 Aug 2023

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Nicola Ryan

Author

Nicola Ryan
BIOFLOW DAPT - Biodegradable polymer SES vs durable polymer ZES in HBR subjects with 1-month DAPT
Didn’t find what you were looking for?